Moreover, Foxp3+ Tregs in glioma can bind to CD80/CD86 on antigen-presenting cells (APCs) through CTLA-4, affecting their efficacy and thus inhibiting T lymphocyte activity (25). This evidence concerns the gene FOXP3 and glioma.